Drugs and Pharmaceuticals
Germany represents the second largest export market for U.S. pharmaceuticals, including prescription, specialty and OTC drugs, after Japan. Between 2010 and 2015, the market is projected to grow annually at 4.8% (prescription drugs at 3.9%), with the fastest growth in the specialized hospital market for new and expensive pharmaceuticals. Recent sales growth has been for drugs for acute conditions such as cancer, rheumatoid arthritis, and multiple sclerosis; but also for chronic conditions such as cardiovascular diseases, diabetes and preventive medicine. The statutory health insurance system accounts for about 80% of the market, with tight reimbursement rules, greater use of generics and downward pressure on generic prices due to the rebate system and the full VAT of 19% levied on drug sales. Opportunities also exist for local production, research and acquisition of German drug firms.
Diagnostic and therapeutic drugs for dementia; auto immune diseases; inflammation; oncology; pain management. Vaccines and cell- and bio-therapeutics; biosimilars.